Chemistry Reference
In-Depth Information
58. Hochster HS, Vogel CL, Burman SL, White R. Activity and safety of vinorelbine
combined with doxorubicin or fluorouracil as first-line therapy in advanced breast
cancer: a stratified phase II study. Oncologist 2001;6:269-277.
59. Barnett CJ, Cullinan GJ, Gerzon K, Hoying RC, Jones WE, Newlon WM, Poore
GA, Robison RL, Sweeney MJ, et al. Structure-activity relationships of dimeric
Catharanthus alkaloids. 1. Deacetyl vinblastine amide vindesine sulfate. J. Med.
Chem. 1978;21:88-96.
60. Sorensen JB, Hansen HH. Is there a role for vindesine in the treatment of non-small
cell lung cancer? Invest. New Drugs 1993;11:103-133.
61. Sorensen JB, Osterlind K, Hansen HH. Vinca alkaloids in the treatment of non-small
cell lung cancer. Cancer Treat. Rev. 1987;14:29-51.
62. Ruckdeschel JC. Etoposide in the management of non-small cell lung cancer. Cancer
1991;67:2533.
63. Gordaliza M, Castro MA, del Corral JM, Feliciano AS. Antitumor properties of
podophyllotoxin and related compounds. Curr. Pharm. Des. 2000;6:1811-1839.
64. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem.
Anticancer Agents 2005;5:363-372.
65. You Y. Podophyllotoxin derivatives: current synthetic approaches for new anticancer
agents. Curr. Pharm. Des. 2005;11:1695-1717.
66. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation
and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.
Experientia 1989;45:209-211.
67. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, Hamel E. Inter-
actions of tubulin with potent natural and synthetic analogs of the antimitotic agent
combretastatin: a structure-activity study. Mol. Pharmacol. 1988;34:200-208.
68. Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW, 3rd,
Shnyder SD, Cooper PA, Bibby MC. Comparative preclinical pharmacokinetic and
metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and
A1 phosphate. Clin. Cancer Res. 2004;10:1446-1453.
69. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A,
Pettit GR, Al-Katib AM. Combretastatin-A4 prodrug induces mitotic catastrophe
in chronic lymphocytic leukemia cell line independent of caspase activation and
polyADP-ribose polymerase cleavage. Clin. Cancer Res. 2002;8:2735-2741.
70. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy:
evaluation of combretastatin A4 phosphate. Anticancer Res. 1999;19:189-195.
71. Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor
activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest.
New Drugs 1996;14:131-137.
72. Phillips DR, White RJ, Cullinane C. DNA sequence-specific adducts of adriamycin
and mitomycin C. FEBS Lett. 1989;246:233-240.
73. Skorobogaty A, White RJ, Phillips DR, Reiss JA. Elucidation of the DNA sequence
preferences of daunomycin. Drug. Des. Deliv. 1988;3:125-151.
74. Skorobogaty A, White RJ, Phillips DR, Reiss JA. The 5'-CA DNA-sequence pref-
erence of daunomycin. FEBS Lett. 1988;227:103-106.
75. Hecht SM. Bleomycin: new perspectives on the mechanism of action. J. Nat. Prod.
2000;63:158-168.
